Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart drug missiles take aim at Hard-to-Treat lung cancer

NCT ID NCT06780085

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killing drug directly to tumor cells. Researchers will compare how well the tumors shrink and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Raludotatug Deruxtecan (R-DXd) and Ifinatamab Deruxtecan (I-DXd)
What this could lead to
If successful, these antibody-drug conjugates could offer a new treatment option for people with advanced nonsquamous lung cancer that has stopped responding to standard therapies.
What could go wrong
This is a Phase 2 trial with only 96 participants, so results are preliminary. The drugs may cause side effects and may not work better than chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AHN Cancer Institute - Allegheny General ( Site 9501)

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • Ankara Bilkent Şehir Hastanesi. ( Site 0142)

    RECRUITING

    Ankara, 06800, Turkey (Türkiye)

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)

    RECRUITING

    Florence, 50134, Italy

  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)

    RECRUITING

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0141)

    RECRUITING

    Adana, 01250, Turkey (Türkiye)

  • Bradfordhill ( Site 0162)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Centro de Estudios Clínicos SAGA ( Site 0161)

    RECRUITING

    Santiago, Region M. de Santiago, 7500653, Chile

  • Charite-Universitaetsmedizin Berlin ( Site 0191)

    RECRUITING

    Berlin, 13353, Germany

  • Ege Universitesi Hastanesi ( Site 0143)

    RECRUITING

    Izmir, 35100, Turkey (Türkiye)

  • European Interbalkan Medical Center ( Site 0205)

    RECRUITING

    Thessaloniki, 570 01, Greece

  • FALP ( Site 0160)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)

    RECRUITING

    Roma, 00168, Italy

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0140)

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Hospital Universitario Quiron Madrid ( Site 0091)

    RECRUITING

    Madrid, 28223, Spain

  • I. U. Cerrahpasa Tip Fakultesi ( Site 0144)

    RECRUITING

    Istanbul, 34098, Turkey (Türkiye)

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)

    RECRUITING

    Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary

  • MedStar Franklin Square Medical Center ( Site 0033)

    RECRUITING

    Baltimore, Maryland, 21237, United States

  • Meir Medical Center ( Site 0071)

    RECRUITING

    Kfar Saba, 4428164, Israel

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Ospedale San Raffaele. ( Site 0171)

    RECRUITING

    Milan, 20132, Italy

  • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)

    RECRUITING

    Győr, Győr-Moson-Sopron, 9024, Hungary

  • Rabin Medical Center ( Site 0074)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0076)

    RECRUITING

    Haifa, 3109601, Israel

  • Shaare Zedek Medical Center ( Site 0075)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0070)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center ( Site 0077)

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)

    RECRUITING

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)

    RECRUITING

    Athens, Attica, 115 27, Greece

  • Universitaetsklinik Tuebingen ( Site 0192)

    RECRUITING

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • University of Kentucky Chandler Medical Center ( Site 0019)

    RECRUITING

    Lexington, Kentucky, 40536-0293, United States

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)

    RECRUITING

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)

    RECRUITING

    Poznan, Greater Poland Voivodeship, 60-569, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.